Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

GMABGenmabSigning up patients

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

Platinum-resistant Ovarian Cancer

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 3
Patients
82 (planned)
Started
Jun 26, 2026
Main results expected
Sep 2027
Fully finished
Dec 2028
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Progression-Free Survival (PFS)

    Measured over: Up to approximately 16 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT07604766 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT07604766) ↗